Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

1. Oral remibrutinib successfully met its primary endpoint in the Phase III RemIND trial, delivering significant symptom relief for chronic inducible urticaria.

2. As a selective BTK inhibitor, this therapy represents the first targeted oral option for patients suffering from cold, pressure, or exercise-induced hives.

Novartis reported today that its selective BTK inhibitor, remibrutinib, successfully met all primary endpoints in the pivotal Phase III RemIND trial for chronic inducible urticaria (CIndU). This is a big win for the estimated 29 million people globally who suffer from hives triggered by specific environmental factors like cold, friction, or exercise. The data showed that patients taking the oral pill achieved significantly higher complete response rates at 12 weeks compared to those on placebo, as confirmed by standardized provocation tests. What makes remibrutinib interesting is its ability to block the release of histamine at the source by inhibiting the Bruton’s tyrosine kinase pathway. For the practicing specialist, this could mean the first targeted oral therapy for a condition that has long been managed with subpar, high-dose antihistamines. The safety profile remained clean, with no liver toxicity signals observed in the study cohort. Novartis has already moved to file a supplemental application with the FDA to bring this to market for inducible subtypes as soon as possible. The oral formulation offers a notable convenience advantage over current injectable options that require clinic visits for administration. By targeting mast cell activation directly, the drug addresses the underlying pathophysiology of wheal formation rather than just neutralizing circulating histamine. Clinicians will need to see if the drug maintains its high efficacy over years of continuous use. It remains unclear if remibrutinib will eventually replace biologics as the first-line preference for refractory or severe cases. However, the data represents a historic first for the large population of patients who currently rely solely on trigger avoidance.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.